ALLO•benzinga•
Allogene Therapeutics To Present Phase 1 Data On ALLO-316 For Advanced CD70 Positive Renal Cell Carcinoma At IKCS And SITC Meetings; FDA Grants RMAT Designation For Potential Single-Infusion AlloCAR T Treatment
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 5, 2024 by benzinga